21-23-Zydus Cadila-Lambda Therapeutic
15 June 2010 | News
21
Zydus Cadila (Formerly Cadila Healthcare)
Zydus Cadila discovers, develops, manufactures and markets a broad range of healthcare products. The company has posted a revenue of Rs 221.22 crore for the fiscal year 2009-2010. The group’s operations range from API to formulations, animal health products and cosmeceuticals. Headquartered in Ahmedabad, the group’s operations spread across the US, Europe, Japan, Brazil, South Africa and 25 other emerging markets. Under the purview of biotechnology research it looks at development of biogeneric therapeutic proteins, antibodies, vaccines, search for novel targets and validation of targets.
The company was in news last year when it received an approval from the Drug Controller General of India (DCGI) to market the H1N1 (swine flu) vaccine. The egg based, inactivated vaccine based on conventional technology has been developed by the group’s researchers at its Vaccine Technology Centre (VTC) in Ahmedabad. VTC further plans to develop a wide spectrum of vaccines against bacterial, viral and protozoal infections. The group also markets anti-rabies and typhoid vaccines. The Zydus Research Centre (ZRC) is the dedicated research and development arm of Zydus Cadila, established in the year 2000.
22
Lambda Therapeutic Research
Lambda Therapeutic Research operates as a contract research organization to deliver clinical development solutions. It’s revenue for the last fiscal year amounted to Rs 145 crore. The company’s services include clinical trials implementation, laboratory and data management, information technology support, medical affairs assistance, quality assurance, and bio analysis. In addition, it conducts pharmacokinetic, bioequivalence, first-in-human and biostatistics study programs. Lambda also provides therapeutic services for dermatology, oncology, rheumatology, cardiovascular, central nervous system and autoimmune deficiencies.
Ahmedabad-headquartered Lambda Therapeutic has additional facilities in Mumbai and Erwitte, Germany. In an inspection conducted by Department of Medical Sciences, Ministry of Public Health, Thailand, in October 2008 at Ahmedabad, the company’s Bioanalytical facility was approved by Ministry of Public Health, Thailand for GLP. Also, in 2008, Lambda received the ANVISA approval for its Ahmedabad facility.
23
Krishidhan Seeds
Krishidhan Seeds clocked biotech revenues of Rs 133.23 crore for the fiscal year. The company develops, produces and distributes proprietary hybrid seeds and selections to Indian farmers. The company has experienced significant sales growth of six times over the last five years. It has reported consolidated revenues of Rs 279 crores (approximately $88 million) for the current financial year.
Krishidhan Seeds has a pan-India presence and offers a diversified portfolio of more than 120 products including field crops, vegetable seeds and crop nutrition. The company’s workforce is 885 people strong. Out of this, 32 are PhDs and 171 are post graduates. The expanse of its activities is across the length and breadth of India. This has resulted in establishment of strong trust and brand equity of Krishidhan among all its stakeholders. The group so far has invested heavily in R&D infrastructure to set up 10 regional research stations across India, and a state-of-the-art biotech facility in its Technology Centre at Jalna.
Zydus Cadila (Formerly Cadila Healthcare)
| CEO | Pankaj R Patel |  |
| Business | Biopharmaceuticals | |
| Start-up Year | 1995 | |
| Biotech Revenue | Rs 147.48 crore | |
| Address | Zydus Tower, Satellite Cross Roads, Ahmedabad – 380015 | |
| Tel | +91-79-26868100 | |
| Fax | +91-79-26862365 | |
| Website | www.zyduscadila.com |
Zydus Cadila discovers, develops, manufactures and markets a broad range of healthcare products. The company has posted a revenue of Rs 221.22 crore for the fiscal year 2009-2010. The group’s operations range from API to formulations, animal health products and cosmeceuticals. Headquartered in Ahmedabad, the group’s operations spread across the US, Europe, Japan, Brazil, South Africa and 25 other emerging markets. Under the purview of biotechnology research it looks at development of biogeneric therapeutic proteins, antibodies, vaccines, search for novel targets and validation of targets.
The company was in news last year when it received an approval from the Drug Controller General of India (DCGI) to market the H1N1 (swine flu) vaccine. The egg based, inactivated vaccine based on conventional technology has been developed by the group’s researchers at its Vaccine Technology Centre (VTC) in Ahmedabad. VTC further plans to develop a wide spectrum of vaccines against bacterial, viral and protozoal infections. The group also markets anti-rabies and typhoid vaccines. The Zydus Research Centre (ZRC) is the dedicated research and development arm of Zydus Cadila, established in the year 2000.
22
Lambda Therapeutic Research
| Director | Ashish Kumar Dasgupta |  |
| Business | Clinical trials implementation, laboratory and data
management and bio analysis |
|
| Start-up Year | 1999 | |
| Biotech Revenue | Rs 145 crore | |
| Address | Near Gujarat High Court, SG Highway, Gota, Ahmedabad
380061, Gujarat |
|
| Tel | +91-79-40202020 | |
| Fax | +91-79-40202021 | |
| Website | www.lambda-cro.com |
Lambda Therapeutic Research operates as a contract research organization to deliver clinical development solutions. It’s revenue for the last fiscal year amounted to Rs 145 crore. The company’s services include clinical trials implementation, laboratory and data management, information technology support, medical affairs assistance, quality assurance, and bio analysis. In addition, it conducts pharmacokinetic, bioequivalence, first-in-human and biostatistics study programs. Lambda also provides therapeutic services for dermatology, oncology, rheumatology, cardiovascular, central nervous system and autoimmune deficiencies.
Ahmedabad-headquartered Lambda Therapeutic has additional facilities in Mumbai and Erwitte, Germany. In an inspection conducted by Department of Medical Sciences, Ministry of Public Health, Thailand, in October 2008 at Ahmedabad, the company’s Bioanalytical facility was approved by Ministry of Public Health, Thailand for GLP. Also, in 2008, Lambda received the ANVISA approval for its Ahmedabad facility.
23
Krishidhan Seeds
| MD | Sushil Karwa |  |
| Business | Production and distribution of hybrid seeds |
|
| Start-up Year | 1996 | |
| Biotech Revenue | Rs 133.23 crore | |
| Address | Krishidhan Bhavan, D3 - D6, Additional MIDC Area,
Aurangabad Road, Jalna, Maharashtra |
|
| Tel | +91-2482-222750 | |
| Fax | +91-2482-222600 | |
| Website | www.krishidhanseeds.com |
Krishidhan Seeds clocked biotech revenues of Rs 133.23 crore for the fiscal year. The company develops, produces and distributes proprietary hybrid seeds and selections to Indian farmers. The company has experienced significant sales growth of six times over the last five years. It has reported consolidated revenues of Rs 279 crores (approximately $88 million) for the current financial year.
Krishidhan Seeds has a pan-India presence and offers a diversified portfolio of more than 120 products including field crops, vegetable seeds and crop nutrition. The company’s workforce is 885 people strong. Out of this, 32 are PhDs and 171 are post graduates. The expanse of its activities is across the length and breadth of India. This has resulted in establishment of strong trust and brand equity of Krishidhan among all its stakeholders. The group so far has invested heavily in R&D infrastructure to set up 10 regional research stations across India, and a state-of-the-art biotech facility in its Technology Centre at Jalna.
